Research in precision medicine requires a continuous supply of high-quality biospecimens. But as the saying goes- “Garbage in garbage out”, meaningful conclusions from the studies can only be drawn when the researchers are assured that the materials used in their research were of good quality. A survey(1) conducted by the National Cancer Institute (NCI) funded cancer […]
Customer Speak “We were looking for a robust and structured system that is able to manage our biobank in a constructive way. We chose OpenSpecimen as the system was able to be customized to our specific needs and the developers, Krishagni were dedicated to biobanking and had a vast depth of experience that we could […]
The short answer is Yes. However, it is important to note that the software itself cannot be compliant. Rather, it is the implementation and use of software that determines compliance. It is achieved only when a study has the procedures, policies, documentation, training, and validation that meets Part-11 requirements. An FDA auditor will review all […]
Managing biospecimen data for longitudinal studies or clinical trials can be challenging. Clinical studies often go on for months or years, and involves complex workflows like kit preparations, tracking upcoming visits, multi-site collections, shipments, and so forth. To manage these types of collections, OpenSpecimen offers a customizable platform to plan, manage and track biospecimens in a […]
This case study describes the adoption of OpenSpecimen at one of the biggest biobanks in gastroenterology (GI) cancer in an academic center in Pittsburgh. Prior to OpenSpecimen, they used an in-house system to store clinical and specimen data. However, it had several shortcomings which were severely impeding their ability to find specimens of research interest. […]
Following is a poster presented by the Victorian Cancer Biobank team on using OpenSpecimen for ‘Improving interoperability and quality of data’ at the ABNA 2019 conference. VCB has collected more than 600,000 biospecimens from a broad range of tumours, and approximately 423,000 biospecimens are currently in our inventory. OpenSpecimen was implemented as the biobank information […]
The Tumor Tissue and Biospecimen Bank (TTAB) at the University of Pennsylvania (Upenn) collects and stores biospecimens for lung cancer, breast cancer, hematologic malignancies, head and neck cancer, GU cancers, and melanomas. TTAB was established as a partnership between the Abramson Cancer Center (ACC) and the Department of Pathology and Laboratory Medicine with a vision […]
Following is a poster on the implementation and usage of OpenSpecimen at the Washington University School of Medicine (WUSM). David Mulvihill, Director of Informatics for Siteman Cancer Center, presented this poster at the ISBER 2019 Conference (Minneapolis). WUSM has been using OpenSpecimen for 10+ years as the “Enterprise” biospecimen management platform. Within WUSM, OpenSpecimen is […]
Current Adoption Status 67 collection protocols used OpenSpecimen Published 67 peer-reviewed articles Supported 20 grants Manages 391,720 specimens for 38,813 study participants 110,969 specimens are sent to the PMAP Precision Medicine platform 40+ active users *Reference: 2019 OpenSpecimen JHU Annual Report The Johns Hopkins University School of Medicine adopted OpenSpecimen in 2016 as a scalable […]
The Oxford Biobank is a population-based biorepository. They currently hold over 400,000 biological samples collected across 20+ studies. Their collection includes biospecimens and data from more than 8,000 healthy 30-50 years old Oxfordshire residents. All participants undergo a detailed examination at a screening visit, donate DNA and give informed consent to be re-approached. Therefore, the […]
